Therefore, while BCL-2-directed therapies offer a promising route to restore apoptosis and improve ATLL outcomes, their success will depend on refined drug selectivity, rational combination design, and careful monitoring of resistance mechanisms in future translational and clinical studies. This evidence concerns the gene BCL2 and adult T-cell leukemia/lymphoma.